-
-
-
-
-
-
-
Sanofi drug gets EU panel backing for progressive multiple sclerosis
-
-
-
-
-
-
-
Sanofi's amlitelimab shows positive results in atopic dermatitis trials
-
-
-
-
-
-
-
Valuation in this big pharma stock continues to be attractive: analyst
-
-
-
-
-
-
-
Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
-
-
-
-
-
-
-
Sanofi (SNY) Reports Q2 EPS of EUR1.59; offers guidance
-
-
-
-
-
-
-
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline
-
-
-
-
-
-
-
Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
-
1,206,301 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

